tiprankstipranks
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market
ALNY
Alnylam Pharma
RESEARCH TOOLSreports
Want to see ALNY full AI Analyst Report?

Alnylam Pharma (ALNY) Stock Forecast & Price Target

1,437 Followers
See the Price Targets and Ratings of:

ALNY Analyst Ratings

Strong Buy
20Ratings
Strong Buy
17 Buy
3 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$446.53
▲(44.20% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $446.53 with a high forecast of $550.00 and a low forecast of $330.00. The average price target represents a 44.20% change from the last price of $309.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"254":"$254","551":"$551","328.25":"$328.3","402.5":"$402.5","476.75":"$476.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":550,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$550.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":446.52941176470586,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$446.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":330,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$330.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[254,328.25,402.5,476.75,551],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,296.11,315.64,335.17,354.7,374.23,393.76,413.28999999999996,432.82,452.35,471.88,491.40999999999997,510.94,530.47,{"y":550,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,296.11,307.6807239819005,319.2514479638009,330.82217194570137,342.3928959276018,353.96361990950226,365.5343438914027,377.10506787330314,388.6757918552036,400.2465158371041,411.8172398190045,423.38796380090497,434.95868778280544,{"y":446.52941176470586,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,296.11,298.7169230769231,301.32384615384615,303.9307692307692,306.53769230769234,309.1446153846154,311.7515384615385,314.35846153846154,316.9653846153846,319.5723076923077,322.1792307692308,324.78615384615387,327.39307692307693,{"y":330,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":460.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":454.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":397.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.73,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.11,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$550.00Average Price Target$446.53Lowest Price Target$330.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on ALNY
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$420
Buy
35.63%
Upside
Reiterated
05/20/26
J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Citi Analyst forecast on ALNY
Unknown Analyst
Citi
Not Ranked
Citi
$380
Buy
22.72%
Upside
Initiated
05/19/26
Alnylam initiated with a Buy at CitiAlnylam initiated with a Buy at Citi
Barclays Analyst forecast on ALNY
Eliana Merle
Barclays
Barclays
$527
Buy
70.19%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Relay Therapeutics (NASDAQ: RLAY) and Repligen (NASDAQ: RGEN)
H.C. Wainwright Analyst forecast on ALNY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$510
Buy
64.70%
Upside
Reiterated
05/05/26
Alnylam Maintained at Buy as Strong TTR-Driven Momentum and Pipeline Progress Support Unchanged $510 Price Target
Canaccord Genuity Analyst forecast on ALNY
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$429
Buy
38.54%
Upside
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT), The Ensign Group (NASDAQ: ENSG) and Alnylam Pharma (NASDAQ: ALNY)
Evercore ISI Analyst forecast on ALNY
Cory Kasimov
Evercore ISI
Evercore ISI
$400
Buy
29.17%
Upside
Reiterated
05/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Alnylam Pharma (NASDAQ: ALNY) and The Ensign Group (NASDAQ: ENSG)
Truist Financial Analyst forecast on ALNY
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
Raymond James Analyst forecast on ALNY
Tiago Fauth
Raymond James
Raymond James
$376→$377
Hold
21.75%
Upside
Reiterated
05/01/26
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on ALNY
Edward Tenthoff
Piper Sandler
Piper Sandler
$489
Buy
57.92%
Upside
Reiterated
05/01/26
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Chardan Capital Analyst forecast on ALNY
Keay Nakae
Chardan Capital
Chardan Capital
$425
Buy
37.25%
Upside
Reiterated
05/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on ALNY
Michael Ulz
Morgan Stanley
Morgan Stanley
$360→$370
Hold
19.49%
Upside
Reiterated
05/01/26
Morgan Stanley Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Bernstein Analyst forecast on ALNY
William Pickering
Bernstein
Bernstein
$448→$447
Buy
44.35%
Upside
Reiterated
05/01/26
Alnylam Pharma (ALNY) Gets a Buy from Bernstein
Oppenheimer Analyst forecast on ALNY
Kostas Biliouris
Oppenheimer
Oppenheimer
$500
Buy
61.47%
Upside
Reiterated
05/01/26
Oppenheimer Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
TD Cowen Analyst forecast on ALNY
Ritu Baral
TD Cowen
TD Cowen
$482
Buy
55.65%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Alignment Healthcare (NASDAQ: ALHC)
William Blair Analyst forecast on ALNY
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
04/30/26
Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on ALNY
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$420
Buy
35.63%
Upside
Reiterated
05/20/26
J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Citi Analyst forecast on ALNY
Unknown Analyst
Citi
Not Ranked
Citi
$380
Buy
22.72%
Upside
Initiated
05/19/26
Alnylam initiated with a Buy at CitiAlnylam initiated with a Buy at Citi
Barclays Analyst forecast on ALNY
Eliana Merle
Barclays
Barclays
$527
Buy
70.19%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Relay Therapeutics (NASDAQ: RLAY) and Repligen (NASDAQ: RGEN)
H.C. Wainwright Analyst forecast on ALNY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$510
Buy
64.70%
Upside
Reiterated
05/05/26
Alnylam Maintained at Buy as Strong TTR-Driven Momentum and Pipeline Progress Support Unchanged $510 Price Target
Canaccord Genuity Analyst forecast on ALNY
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$429
Buy
38.54%
Upside
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT), The Ensign Group (NASDAQ: ENSG) and Alnylam Pharma (NASDAQ: ALNY)
Evercore ISI Analyst forecast on ALNY
Cory Kasimov
Evercore ISI
Evercore ISI
$400
Buy
29.17%
Upside
Reiterated
05/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Alnylam Pharma (NASDAQ: ALNY) and The Ensign Group (NASDAQ: ENSG)
Truist Financial Analyst forecast on ALNY
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
Raymond James Analyst forecast on ALNY
Tiago Fauth
Raymond James
Raymond James
$376→$377
Hold
21.75%
Upside
Reiterated
05/01/26
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on ALNY
Edward Tenthoff
Piper Sandler
Piper Sandler
$489
Buy
57.92%
Upside
Reiterated
05/01/26
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Chardan Capital Analyst forecast on ALNY
Keay Nakae
Chardan Capital
Chardan Capital
$425
Buy
37.25%
Upside
Reiterated
05/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on ALNY
Michael Ulz
Morgan Stanley
Morgan Stanley
$360→$370
Hold
19.49%
Upside
Reiterated
05/01/26
Morgan Stanley Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Bernstein Analyst forecast on ALNY
William Pickering
Bernstein
Bernstein
$448→$447
Buy
44.35%
Upside
Reiterated
05/01/26
Alnylam Pharma (ALNY) Gets a Buy from Bernstein
Oppenheimer Analyst forecast on ALNY
Kostas Biliouris
Oppenheimer
Oppenheimer
$500
Buy
61.47%
Upside
Reiterated
05/01/26
Oppenheimer Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
TD Cowen Analyst forecast on ALNY
Ritu Baral
TD Cowen
TD Cowen
$482
Buy
55.65%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Alignment Healthcare (NASDAQ: ALHC)
William Blair Analyst forecast on ALNY
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
04/30/26
Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months
Keay NakaeChardan Capital
Success Rate
26/41 ratings generated profit
63%
Average Return
+6.09%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 63.41% of your transactions generating a profit, with an average return of +6.09% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
20/26 ratings generated profit
77%
Average Return
+30.27%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +30.27% per trade.
2 Years
Whitney IjemCanaccord Genuity
Success Rate
23/26 ratings generated profit
88%
Average Return
+46.84%
Copying Whitney Ijem's trades and holding each position for 2 Years would result in 88.46% of your transactions generating a profit, with an average return of +46.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
11
16
20
18
Buy
22
28
32
19
17
Hold
9
9
10
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
34
48
58
45
41
In the current month, ALNY has received 35 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 446.53.
Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is $1.63 with a range of $1.00 to $2.16. The previous quarter’s EPS was $1.51. ALNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALNY is $1.63 with a range of $1.00 to $2.16. The previous quarter’s EPS was $1.51. ALNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $1.32B with a range of $1.22B to $1.42B. The previous quarter’s sales results were $1.17B. ALNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.
Next quarter’s sales forecast for ALNY is $1.32B with a range of $1.22B to $1.42B. The previous quarter’s sales results were $1.17B. ALNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 446.53.
    What is ALNY’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 44.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALNY a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s price target?
            The average price target for Alnylam Pharmaceuticals is 446.53. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $550.00 ,the lowest forecast is $330.00. The average price target represents 44.20% Increase from the current price of $309.66.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of ALNY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.